Search Results
87 items found for " Krystal R Capers"
Posts (54)
- A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology in...
August 2022 A NanoBRET-Based H 3 R Conformational Biosensor to Study Real-Time H 3 Receptor Pharmacology
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare disorders, today announced that the Company entered into a royalty-based financing with an affiliate of R-Bridge Healthcare Fund (the R-Bridge Financing)."
- 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry. October 5-7, 2022, Verona, Italy
August 2022 "GPCRs in Medicinal Chemistry Event 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry Dates Wednesday-Friday, 5th-7th October 2022 Place Evotec Campus Levi-Montalcini, Verona, Italy Downloads and Links Registration closing dates: 6th September – registration against invoice (bank transfers): Tuesday, 6th September 30th September – online registration (card payments)" Read more at the source #DrGPCR #GPCR #IndustryNews
Other Pages (33)
- DANGER Signals Activate G-Protein Receptor Kinases Suppressing Neutrophil Function and Predisposing to Infection After Tissue Trauma
Jinbong Park , David Gallo , Sidharth Shankar , Barbora Konecna , Yohan Han , Valerie Banner-Goodspeed , Krystal R Capers , Seong-Gyu Ko , Leo E Otterbein , Kiyoshi Itagaki , Carl J Hauser. Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR papers
- Ep 96 with R. Scott Struthers
GPCR Podcast << Back to podcast list Scott Struthers R. R. Scott Struthers on the web LinkedIn Google Scholar Crinetics Radionetics Dr.
- Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia
R) AML. The current study aimed to identify molecular predictors of response to ONV + DAC in R/R AML patients A total of 44 R/R AML patients were treated with ONV + DAC and considered evaluable for efficacy. PLK1 inhibition with ONV in combination with DAC could be a potential therapy in R/R AML patients, particularly Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call for GPCR papers